Loading…

Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand

Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2011-07, Vol.204 (suppl_1), p.S62-S70
Main Authors: Smith, Graegar, Michelson, Joshua, Singh, Rohit, Dabbagh, Alya, Hoekstra, Edward, van den Ent, Maya, Mallya, Apoorva
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193
cites
container_end_page S70
container_issue suppl_1
container_start_page S62
container_title The Journal of infectious diseases
container_volume 204
creator Smith, Graegar
Michelson, Joshua
Singh, Rohit
Dabbagh, Alya
Hoekstra, Edward
van den Ent, Maya
Mallya, Apoorva
description Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion MCV doses must be administered during 2010-2025 to maintain current measles programs, and 5.9 billion doses would likely be needed with a 2020 eradication goal; in the most intensive scenario, demand could increase to 7.5 billion doses. These volumes are within existing and planned MCV-manufacturing capacity, although there are risks. In some markets, capacity is concentrated: Supply-chain disruptions could reduce supply or increase prices. Mitigation strategies could include stockpiling, long-term contracts, and further coordination with manufacturers.
doi_str_mv 10.1093/infdis/jir130
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_872434879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>41230446</jstor_id><oup_id>10.1093/infdis/jir130</oup_id><sourcerecordid>41230446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193</originalsourceid><addsrcrecordid>eNqF0DtPwzAUBWALgWh5jIwgb7AE7Nh1kglVpUAlEAMVa-TY162r1A52MvTfkyrQlenoXn06w0HoipJ7Sgr2YJ3RNj5sbKCMHKExnbAsEYKyYzQmJE0TmhfFCJ3FuCGEcCayUzRKqRAipZMxahcRL9cQAM-d71Zr_CWVsg5w6_E8SG2VbAG_g4w1xEc8dXjhWliF_qv7S9a7aCP25o8kM-9aaZ11q0PVZ9c09Q5Lp_ETbPu4QCdG1hEuf_McLZ_ny9lr8vbxsphN3xLFctEmtGKaVpQawaWWimvNucyF5mZSGMK4NIpnQk0IkaBMVeVK51UKQKhgihbsHN0OtU3w3x3EttzaqKCupQPfxTLPUs54nu1lMkgVfIwBTNkEu5VhV1JS7mcuh5nLYebe3_w2d9UW9EH_7dqDuwH4rvm363qgm9j6cMCcpoxwLtgPCJCTYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>872434879</pqid></control><display><type>article</type><title>Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals Online</source><creator>Smith, Graegar ; Michelson, Joshua ; Singh, Rohit ; Dabbagh, Alya ; Hoekstra, Edward ; van den Ent, Maya ; Mallya, Apoorva</creator><creatorcontrib>Smith, Graegar ; Michelson, Joshua ; Singh, Rohit ; Dabbagh, Alya ; Hoekstra, Edward ; van den Ent, Maya ; Mallya, Apoorva</creatorcontrib><description>Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion MCV doses must be administered during 2010-2025 to maintain current measles programs, and 5.9 billion doses would likely be needed with a 2020 eradication goal; in the most intensive scenario, demand could increase to 7.5 billion doses. These volumes are within existing and planned MCV-manufacturing capacity, although there are risks. In some markets, capacity is concentrated: Supply-chain disruptions could reduce supply or increase prices. Mitigation strategies could include stockpiling, long-term contracts, and further coordination with manufacturers.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jir130</identifier><identifier>PMID: 21666215</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Child, Preschool ; Countries ; Developed Countries ; Developing Countries ; FEASIBILITY OF MEASLES ERADICATION ; Financial risk ; Forecasting ; Global Health ; Humans ; Immunization ; Infant ; Measels mumps rubella vaccine ; Measles ; Measles - prevention &amp; control ; Measles Vaccine - economics ; Measles Vaccine - supply &amp; distribution ; Measles vaccines ; Political campaigns ; Rubella ; Supply ; Vaccination ; Vaccination - economics</subject><ispartof>The Journal of infectious diseases, 2011-07, Vol.204 (suppl_1), p.S62-S70</ispartof><rights>Copyright © 2011 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2011</rights><rights>The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/41230446$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/41230446$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21666215$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Graegar</creatorcontrib><creatorcontrib>Michelson, Joshua</creatorcontrib><creatorcontrib>Singh, Rohit</creatorcontrib><creatorcontrib>Dabbagh, Alya</creatorcontrib><creatorcontrib>Hoekstra, Edward</creatorcontrib><creatorcontrib>van den Ent, Maya</creatorcontrib><creatorcontrib>Mallya, Apoorva</creatorcontrib><title>Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion MCV doses must be administered during 2010-2025 to maintain current measles programs, and 5.9 billion doses would likely be needed with a 2020 eradication goal; in the most intensive scenario, demand could increase to 7.5 billion doses. These volumes are within existing and planned MCV-manufacturing capacity, although there are risks. In some markets, capacity is concentrated: Supply-chain disruptions could reduce supply or increase prices. Mitigation strategies could include stockpiling, long-term contracts, and further coordination with manufacturers.</description><subject>Child, Preschool</subject><subject>Countries</subject><subject>Developed Countries</subject><subject>Developing Countries</subject><subject>FEASIBILITY OF MEASLES ERADICATION</subject><subject>Financial risk</subject><subject>Forecasting</subject><subject>Global Health</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infant</subject><subject>Measels mumps rubella vaccine</subject><subject>Measles</subject><subject>Measles - prevention &amp; control</subject><subject>Measles Vaccine - economics</subject><subject>Measles Vaccine - supply &amp; distribution</subject><subject>Measles vaccines</subject><subject>Political campaigns</subject><subject>Rubella</subject><subject>Supply</subject><subject>Vaccination</subject><subject>Vaccination - economics</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqF0DtPwzAUBWALgWh5jIwgb7AE7Nh1kglVpUAlEAMVa-TY162r1A52MvTfkyrQlenoXn06w0HoipJ7Sgr2YJ3RNj5sbKCMHKExnbAsEYKyYzQmJE0TmhfFCJ3FuCGEcCayUzRKqRAipZMxahcRL9cQAM-d71Zr_CWVsg5w6_E8SG2VbAG_g4w1xEc8dXjhWliF_qv7S9a7aCP25o8kM-9aaZ11q0PVZ9c09Q5Lp_ETbPu4QCdG1hEuf_McLZ_ny9lr8vbxsphN3xLFctEmtGKaVpQawaWWimvNucyF5mZSGMK4NIpnQk0IkaBMVeVK51UKQKhgihbsHN0OtU3w3x3EttzaqKCupQPfxTLPUs54nu1lMkgVfIwBTNkEu5VhV1JS7mcuh5nLYebe3_w2d9UW9EH_7dqDuwH4rvm363qgm9j6cMCcpoxwLtgPCJCTYA</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Smith, Graegar</creator><creator>Michelson, Joshua</creator><creator>Singh, Rohit</creator><creator>Dabbagh, Alya</creator><creator>Hoekstra, Edward</creator><creator>van den Ent, Maya</creator><creator>Mallya, Apoorva</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand</title><author>Smith, Graegar ; Michelson, Joshua ; Singh, Rohit ; Dabbagh, Alya ; Hoekstra, Edward ; van den Ent, Maya ; Mallya, Apoorva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Child, Preschool</topic><topic>Countries</topic><topic>Developed Countries</topic><topic>Developing Countries</topic><topic>FEASIBILITY OF MEASLES ERADICATION</topic><topic>Financial risk</topic><topic>Forecasting</topic><topic>Global Health</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infant</topic><topic>Measels mumps rubella vaccine</topic><topic>Measles</topic><topic>Measles - prevention &amp; control</topic><topic>Measles Vaccine - economics</topic><topic>Measles Vaccine - supply &amp; distribution</topic><topic>Measles vaccines</topic><topic>Political campaigns</topic><topic>Rubella</topic><topic>Supply</topic><topic>Vaccination</topic><topic>Vaccination - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Graegar</creatorcontrib><creatorcontrib>Michelson, Joshua</creatorcontrib><creatorcontrib>Singh, Rohit</creatorcontrib><creatorcontrib>Dabbagh, Alya</creatorcontrib><creatorcontrib>Hoekstra, Edward</creatorcontrib><creatorcontrib>van den Ent, Maya</creatorcontrib><creatorcontrib>Mallya, Apoorva</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Graegar</au><au>Michelson, Joshua</au><au>Singh, Rohit</au><au>Dabbagh, Alya</au><au>Hoekstra, Edward</au><au>van den Ent, Maya</au><au>Mallya, Apoorva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>204</volume><issue>suppl_1</issue><spage>S62</spage><epage>S70</epage><pages>S62-S70</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Responding to regional advancements in combating measles, the World Health Organization in May 2008 called for an assessment of the feasibility of measles eradication, including whether sufficient vaccine supply exists. Interviews with international health officials and vaccine-makers provided data for a detailed model of worldwide demand and supply for measles-containing vaccine (MCV). The study projected global MCV demand through 2025 with and without a global eradication goal. The study found that 5.2 billion MCV doses must be administered during 2010-2025 to maintain current measles programs, and 5.9 billion doses would likely be needed with a 2020 eradication goal; in the most intensive scenario, demand could increase to 7.5 billion doses. These volumes are within existing and planned MCV-manufacturing capacity, although there are risks. In some markets, capacity is concentrated: Supply-chain disruptions could reduce supply or increase prices. Mitigation strategies could include stockpiling, long-term contracts, and further coordination with manufacturers.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>21666215</pmid><doi>10.1093/infdis/jir130</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1899
ispartof The Journal of infectious diseases, 2011-07, Vol.204 (suppl_1), p.S62-S70
issn 0022-1899
1537-6613
language eng
recordid cdi_proquest_miscellaneous_872434879
source JSTOR Archival Journals and Primary Sources Collection; Oxford Journals Online
subjects Child, Preschool
Countries
Developed Countries
Developing Countries
FEASIBILITY OF MEASLES ERADICATION
Financial risk
Forecasting
Global Health
Humans
Immunization
Infant
Measels mumps rubella vaccine
Measles
Measles - prevention & control
Measles Vaccine - economics
Measles Vaccine - supply & distribution
Measles vaccines
Political campaigns
Rubella
Supply
Vaccination
Vaccination - economics
title Is There Enough Vaccine to Eradicate Measles? An Integrated Analysis of Measles-Containing Vaccine Supply and Demand
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T14%3A58%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20There%20Enough%20Vaccine%20to%20Eradicate%20Measles?%20An%20Integrated%20Analysis%20of%20Measles-Containing%20Vaccine%20Supply%20and%20Demand&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Smith,%20Graegar&rft.date=2011-07-01&rft.volume=204&rft.issue=suppl_1&rft.spage=S62&rft.epage=S70&rft.pages=S62-S70&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jir130&rft_dat=%3Cjstor_proqu%3E41230446%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c386t-1b3d1b11f64adac4dd44a86d4f59f034afc476c500aecfbb8cd8b2ee0163c193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=872434879&rft_id=info:pmid/21666215&rft_jstor_id=41230446&rft_oup_id=10.1093/infdis/jir130&rfr_iscdi=true